Rx Note

Introduction As stated in the Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings (Procedures) , NIOSH defines a hazardous drug as a drug that is Approved for use in humans by FDA CDER, Not otherwise regulated by the U.S. Nuclear Regulatory Commission, and Either Is accompanied by prescribing information in the "package insert" that includes manufacturer's special handling information (MSHI) to protect workers handling the drug, or Is identified as a carcinogenic hazard, development hazard, reproductive hazard, genotoxic hazard, or other health hazard by exhibiting one or more of the following toxicity criteria in humans, animal models or in vitro systems. Carcinogenicity Developmental toxicity (including teratogenicity) Reproductive toxicity Genotoxicity Organ toxicity at low doses, or a Structure and toxicity profile that mimics existing drugs determined hazardous by exhibiting any one of the previous five toxicity types. However, if a ...

Introduction Cancer is a group of diseases characterized by abnormal cell growth that can invade or spread to other parts of the body. These are in contrast to benign tumours, which do not spread. A carcinogen can be defined as a substance or an exposure that has the potential to cause cancer. Several national and international agencies review available scientific evidence to assess the cancer-causing potential of various substances. International Agency for Research on Cancer (IARC) The IARC , established in 1965, is part of the World Health Organization (WHO). Since 1971, more than 1000 agents have been evaluated , of which more than500 have been identified as carcinogenic, probably carcinogenic or possibly carcinogenic to humans. The Working Group classifies an agent into one of four categories. Group 1: Carcinogenic to humans Group 2A: Probably carcinogenic to humans Group 2B: Possibly carcinogenic to humans Group 3: Not classifiable as to its carcinogenicity in humans The classifi...